Assignee
INVETX INC
US·9 granted patents·16 pending applications·9 citations·filing 2020–2025
Top patents by PatentIndex Score
25 records- 0194US11498953B2Compositions for increasing half-life of a therapeutic agent in felines and methods of useINVETX INC·Filed 2021·Granted Nov 15, 2022·6 cites·21 claims
- 0291US11434276B2Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of useINVETX INC·Filed 2021·Granted Sep 6, 2022·2 cites·13 claims
- 0390US11739135B2Compositions for increasing half-life of a therapeutic agent in felines and methods of useINVETX INC·Filed 2022·Granted Aug 29, 2023·1 cites·9 claims
- 0485US2024166749A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 0585US2024239896A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 0685US2024166748A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 0785US2024239897A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 0881US2023279118A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2022·Application pending·0 cites
- 0980US2025304650A1Compositions for increasing half-life of a therapeutic agent in felines and methods of useINVETX INC·Filed 2025·Application pending·0 cites
- 1079US12344650B2Compositions for increasing half-life of a therapeutic agent in felines and methods of useINVETX INC·Filed 2022·Granted Jul 1, 2025·0 cites·18 claims
- 1177US12378308B2Anti-NGF antibodies and uses thereofINVETX INC·Filed 2024·Granted Aug 5, 2025·0 cites·27 claims
- 1277US2024327497A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 1375US12110322B2Anti-NGF antibodies and uses thereofINVETX INC·Filed 2023·Granted Oct 8, 2024·0 cites·30 claims
- 1475US2025197478A1Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of useINVETX INC·Filed 2024·Application pending·0 cites
- 1571US11542333B2Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2020·Granted Jan 3, 2023·0 cites·9 claims
- 1671US2023127241A1Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2022·Application pending·0 cites
- 1770US11548949B2Compositions for increasing half-life of a therapeutic agent in canines and methods of useINVETX INC·Filed 2020·Granted Jan 10, 2023·0 cites·7 claims
- 1869US2025011410A1Anti-ngf antibodies and uses thereofINVETX INC·Filed 2022·Application pending·0 cites
- 1967US2024209096A1Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of useINVETX INC·Filed 2023·Application pending·0 cites
- 2067US2024209062A1Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of useINVETX INC·Filed 2023·Application pending·0 cites
- 2166US2025188176A1Anti-il-4ra antibodies and uses thereofINVETX INC·Filed 2024·Application pending·0 cites
- 2265US12103961B2Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of useINVETX INC·Filed 2021·Granted Oct 1, 2024·0 cites·28 claims
- 2365US2025051435A1Anti-il-5 antibodies and uses thereofINVETX INC·Filed 2024·Application pending·0 cites
- 2459US2024392009A1Pharmaceutical compositions for antibodies and making and using the sameINVETX INC·Filed 2024·Application pending·0 cites
- 2547US2025257142A1Anti-il-31ra antibodies and uses thereofINVETX INC·Filed 2025·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →